ELIGIBILITY:

Documented B-cell Non-Hodgkin's Lymphoma

Small lymphocytic lymphoma (ALC \< 5,000 cells/mm3)

Marginal zone B-cell lymphoma (nodal, extranodal, or splenic types)

Lymphoplasmacytic lymphoma

Follicular center lymphoma, follicular

Disease documented to be refractory to a full-course of the most recent rituximab therapy (single agent or combination)

At least 1 prior chemotherapy regimen and maximum of 3 prior chemotherapy regimens

Bidimensionally measurable disease (by CT scan) with at least one lesion measuring ≥ 2.0 cm in a single dimension

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab